

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
21 September 2017 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **No Administrative Meeting (BAP members report no later than 8:45 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drugs/drug classes during the August 2017 meeting:

- ***Drug Class Reviews***
 - ***Basal Insulin Analogs***
 - ***Corticosteroids - Immune Modulators Drug Class—Hereditary Angioedema Agents (HAE) Subclass***
 - ***Antiretroviral Agents: Human Immunodeficiency Virus (HIV)***
- ***Newly-Approved Drugs per CFR 199.21(g)(5)***
 - ***abaloparatide (Tymlos) injection – Osteoporosis Agents***
 - ***brigatinib (Alunbrig) – Oral Oncology Agents for Lung Cancer***
 - ***brodalumab (Siliq) injection – Targeted Immunomodulatory Biologics (TIBs)***
 - ***dronabinol (Syndros) oral solution – Antiemetic and Antivertigo Agents***
 - ***fluticasone/salmeterol (AirDuo RespiClick) oral inhaler – Inhaled Corticosteroids/Long-Acting Beta Agonists (ICS/LABAs)***
 - ***methotrexate (Xatmep) oral solution – Antirheumatic Drugs***
 - ***mixed amphetamine salts ER (Mydayis) – Attention Deficit Hyperactivity Disorder (ADHD) Drugs***
 - ***midostaurin (Rydapt) – Oral Oncology Agents for Acute Myeloid Leukemia (AML)***
 - ***morphine sulfate ER (Morphabond XR) – Narcotic Analgesics***
 - ***niraparib (Zejula) – Oral Oncology Agents for Ovarian Cancer***

- *prasterone (Intrarosa) vaginal insert – Vaginal Lubricants*
- *ribociclib/letrozole (Kisqali Femara Co-Pack)—Oral Oncologic Agents for Breast Cancer*
- *safinamide (Xadago) – Parkinson’s Disease Drugs*
- *sarilumab (Kevzara) injection – TIBs*
- *valbenazine (Ingrezza) – Neuromuscular Miscellaneous Agents*
- *Utilization Management Issues*
 - *Prior Authorization Criteria—New Criteria*
 - *TIBs: guselkumab (Tremfya)*
 - *Gastrointestinal-2 Agents for Opioid-Induced Constipation (OIC): naloxegol (Movantik) and methylnaltrexone (Relistor)*
 - *Prior Authorization Criteria—Updated Criteria*
 - *Acne Agents—Topical Acne and Rosacea Agents: dapsone gel 5% and 7.5% (Aczone)*
 - *TIBs: tocilizumab (Actemra)*
 - *Ophthalmic Immunomodulatory Agents: lifitegrast (Xiidra)*
 - *Corticosteroids – Immune Modulators: crisaborole (Eucrisa)*
 - *Proton Pump Inhibitors (PPIs): esomeprazole delayed release packets for suspension (Nexium Packets)*
 - *Non-Insulin Diabetes Drugs: Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors*
- *National Defense Authorization Act (NDAA) 2008, Section 703 Actions*
- *Prenatal Vitamins and other Products Losing Prescription Status in First DataBank*
- *NDAA 2017 Pilot Program: Incorporation of Value-Based Health Care in Purchased Care Component of TRICARE and Medication Adherence (Addendum to the August P&T Committee meeting)*
- *Panel Discussions*

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.